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Objectives: To assess the effect of cardiopulmonary bypass on allograft
function and recipient survival in double-lung transplantation. Methods:
Retrospective review of 94 double-lung transplantations. Results: Cardio-
pulmonary bypass was used in 37 patients (CPB); 57 transplantations were
accomplished without bypass (no-CPB). Bypass was routinely used for
patients with pulmonary hypertension (n 5 27) and for two recipients
undergoing en bloc transplantation. Cardiopulmonary bypass was required
in eight (12.3%) of the remaining 65 patients. Mean ischemic time was
longer in the CPB group (346 vs 315 minutes, p 5 0.04). The CPB group
required more perioperative blood (11.4 vs 6.0 units, p 5 0.01). Allograft
function, assessed by the arterial/alveolar oxygen tension ratio, was better
in the no-CPB group at 12 and 24 hours after operation (0.54 vs 0.39 at 12
hours, p 5 0.002; and 0.63 vs 0.38 at 24 hours, p 5 0.001). The CPB group
had more severe pulmonary infiltrates at both 1 and 24 hours (p 5 0.005).
Diffuse alveolar damage was more common in the CPB group (69% vs 35%,
p 5 0.002). Median duration of intubation was longer in the CPB group (10
days) than in the no-CPB group (2 days, p 5 0.002). The 30-day mortality
rate (13.5% vs 7.0% in the CPB and no-CPB groups) and 1-year survival
(65% vs 67%, CPB and no-CPB) were not significantly different. Conclu-
sions: In the absence of pulmonary hypertension, cardiopulmonary bypass
is only occasionally necessary in double-lung transplantation. Bypass is
associated with substantial early allograft dysfunction after transplanta-
tion. (J Thorac Cardiovasc Surg 1998;115:990-7)
Lung transplantation for individuals with end-stage pulmonary disease was first performed suc-
cessfully in the context of heart-lung transplanta-
tion.1 Pressures to maximally use scarce donor
organs stimulated increased application of isolated
lung transplantation.2 On the basis of experience
with heart-lung transplantation, double-lung trans-
plantation was initially performed en bloc, with
anastomosis of the airway at the tracheal bifurcation
and mandatory use of cardiopulmonary bypass
(CPB). Complications related to ischemia of the
bronchi and trachea around the carina prompted
adoption of sequential single-lung implantation as
the method of choice for double-lung transplanta-
tion.3, 4 In addition to more robust anastomoses at
the bronchial level, use of CPB was no longer
necessary in all cases. There is experimental5 and
clinical6 evidence that CPB contributes to allograft
dysfunction after pulmonary transplantation. We
reviewed our clinical experience to assess the impact
of CPB on early allograft function and recipient
survival, and to define the relative requirements and
indications for bypass in double-lung transplanta-
tion.
Patients and methods
Patient population. One hundred adult (age . 15
years) double-lung transplantations were performed on 98
patients at the University of Pittsburgh Medical Center
betweeen January 1990 and July 1995. Six transplantations
performed with the use of CPB were excluded, leaving 94
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for analysis. Four excluded patients were receiving extra-
corporeal life support (ECLS) before transplantation
(three retransplantations and one primary respiratory
failure). The two others included a 40-year-old man with
Eisenmenger’s syndrome in whom severe systemic hypo-
tension (systolic pressure , 30 mm Hg) developed before
initiation of CPB. This markedly vasodilated state per-
sisted, and he died in the operating room. The final
excluded patient was a 53-year-old man with pulmonary
fibrosis who received an oversized double-lung graft that
prevented primary closure of the chest. Bilateral upper
lobectomies failed to prevent death from hypoxia, which
occurred 8 days after the operation.
Donor selection and perioperative management. Do-
nors were less than 60 years of age, had clear chest
radiographs, were able to maintain an acceptable arterial
oxygen tension (PaO2 on an inspired oxygen fraction
[FiO2] of 100% and a positive end-expiratory pressure of 5
cm H2O), were free of infected sputum, had normal
findings at bronchoscopy, and were of appropriate size
match with the recipient.7-10 Pulmonary preservation was
carried out with Euro-Collins solution early in the expe-
rience (through April 1991) and thereafter with University
of Wisconsin solution. Alprostadil (prostaglandin E1, 500
mg) was infused into the superior vena cava before
infusion of preservation solution. Recipients underwent
standard pulmonary function testing before transplanta-
tion and determination of left and right ventricular ejec-
tion fractions by noninvasive radionuclide examination.
For those patients requiring CPB, duration of bypass was
recorded. Ischemic times were defined as the interval
from donor crossclamping to reperfusion and were re-
corded for each lung. Intraoperative and postoperative
hemodynamic data were obtained with an indwelling
pulmonary artery catheter.
Indications for CPB. CPB was routinely used in all
patients with primary or secondary pulmonary hyperten-
sion (n 5 27) or for those patients who underwent en-bloc
double-lung transplantation early in the series (n 5 6). In
all other cases, bypass was used only when hemodynamic,
technical, or other intraoperative factors made it neces-
sary.
Assessment of early allograft function. Chest radio-
graphs were obtained at 0 and 24 hours after the opera-
tion. A semiquantitative scale was used to assess the
degree of pulmonary allograft injury, with scoring as
follows: 0, no abnormal findings; 1, perihilar infiltrate; 2,
infiltrate localized to a limited lung field; 3, diffuse mod-
erate interstitial and alveolar infiltrate; 4, diffuse severe
interstitial and alveolar infiltrate. Each lung was graded
independently and a mean score was calculated. Arterial
blood gases were obtained at multiple intervals after
transplantation and used to calculate the arterial/alveolar
oxygen tension ratio (a/A O2 ratio) and the PaO2/FiO2
ratio. The alveolar oxygen tension (PAO2) was calculated
as follows: PAO2 5 (760 - PH2O)FiO2 – 1.25 PaCO2, where
PH2O is the water vapor partial pressure, assumed to be 47
mm Hg at 37° C, Fio2 is the inspired fraction of oxygen,
and PaCO2 is the arterial partial pressure of carbon
dioxide.11 The diagnosis of diffuse alveolar damage
(DAD) was assigned based on histology from biopsy or
autopsy specimens. Blood bank records were reviewed,
and the number of units of packed red blood cells
transfused in the 72-hour perioperative period (beginning
at time of arrival in the operating room) were tabulated.
Time of intubation, length of stay in the intensive care
unit, and patient survival at 30 days and 1 year after
transplantation were recorded.
Statistical analysis. Statistical computations were car-
ried out with JMP software (SAS Institute, Cary, N.C.).
Comparisons between patient characteristics, mean allo-
graft ischemic times, perioperative blood transfusion re-
quirements, a/A O2 ratios, and PaO2/FiO2 ratios in the two
groups were carried out with the unpaired t test. Compar-
ison of mean chest radiographic scores and deaths was
calculated with the x2 likelihood ratio. Fisher’s exact test
was used to compare the need for ECLS in the two
groups. The Kruskal-Wallis rank sum test was applied to
assess duration of intubation and length of stay in the
intensive care unit. Multiple logistic regression analysis
was applied to assess the effect of various donor, recipient,
and perioperative variables on two measures of outcome,
a requirement for prolonged intubation (.7 days) and
Table I. Possible risk factors for prolonged
posttransplantation intubation and mortality
included in the multivariate analysis
Use of CPB
Recipient diagnosis
Allograft ischemic time
Year of operation
Recipient age
Recipient sex
Donor age
Table II. Patient characteristics
Characteristic CPB No-CPB p Value
No. of patients 37 57
Disease:
Pulmonary hypertension 27 0
Cystic fibrosis 3 38
Chronic obstructive pul-
monary disease
1 12
Bronchiectasis 3 6
Pulmonary fibrosis 1 1
Other 2 0
Age 38 6 10 34 6 11 0.15
Gender 0.06
Male (%) 12 (32) 30 (53)
Female (%) 25 (68) 27 (47)
FEV1 (% predicted) 66 6 26 22 6 7 0.001
FVC (% predicted) 75 6 21 42 6 15 0.001
DLCO (%) 68 6 27 53 6 21 0.01
RVEF (%) 32 6 15 43 6 9 0.001
LVEF (%) 63 6 13 64 6 9 0.83
Donor PaO2/FiO2 (mm Hg) 464 6 89 497 6 78 0.14
Donor age 28 6 13 27 6 12 0.45
FEV1, Forced expiratory volume in 1 second; FVC, forced vital capacity;
DLCO, diffusing capacity of carbon monoxide; RVEF, right ventricular
ejection fraction; LVEF, left ventricular ejection fraction.
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1-month survival. Possible risk factors affecting outcome
that were included in the analysis are listed in Table I.
Results
Recipient and donor characteristics. CPB was
used for 37 patients; 57 transplantations were
accomplished without bypass (no-CPB). Compar-
ison of recipient- and donor-related characteris-
tics between the CPB and no-CPB groups is
detailed in Table II. Mandatory use of CPB for
recipients with pulmonary hypertension explains
the markedly different patterns of preoperative
pulmonary function tests in the two groups and
the lower right ventricular ejection fraction in the
CPB group. Although all patients with pulmonary
hypertension underwent transplantation on by-
pass, use of CPB was largely avoided in other
disease categories. Three of nine (33%) patients
undergoing transplantation for bronchiectasis
needed CPB support, and only 3 of 41 (7%) of
those patients with cystic fibrosis needed CPB.
Finally, although 1 of 13 patients with chronic
obstructive pulmonary disease required CPB, this
was an en-bloc transplantation.
Indications for bypass. Indications for CPB are
listed in Table III. Excluding transplantations for
pulmonary hypertension and early en-bloc trans-
plantations (n 5 29), CPB was required in 8 of the
remaining 65 recipients (12.3%). The most common
scenario in which CPB was needed was during initial
hilar dissection: single-lung ventilation caused hypo-
tension and hypoxemia, which prompted initiation
of bypass. In one instance CPB was used to permit
safe dissection in a patient undergoing late reopera-
tion after a heart-lung transplantation, and in an-
other (done early in our experience) bypass was
used electively. Finally, one patient required initia-
tion of bypass after implantation of the first lung. In
this case, crossclamping of the (remaining) pulmo-
nary artery precipitated hypotension and right ven-
tricular dilation.
Duration of CPB and allograft ischemic times.
The mean duration of bypass was 240 6 43 minutes.
Ischemic times for the first and second implanted
lungs are detailed in Table IV. The mean ischemic
time for both grafts was approximately 30 minutes
longer in the group requiring CPB (p 5 0.04). Blood
use in the 72-hour perioperative period was higher
for the group requiring bypass (11.4 vs 6.0 units
packed red blood cells, p 5 0.01).
Preimplantation and postimplantation hemody-
namics. Mean pulmonary artery pressures mea-
sured before transplantation reflected the predom-
inance of pulmonary hypertension in the CPB group
(Fig. 1). Although pulmonary artery systolic pres-
sures before transplantation were markedly higher
in the CPB group (89 vs 39 mm Hg), they were
similar after transplantation (39 vs 34, respectively).
Fig. 1. Preimplantation and postimplantation hemody-
namics in the CPB and no-CPB groups. PA, Pulmonary
artery; tx, transplantation.
Table III. Indications for CPB
Indication
No. of
patients
En-bloc transplantation 6
Pulmonary hypertension 23*
Hypoxemia and hypotension on one-lung ventilation
during initial hilar dissection, before crossclamping
5
Hypotension and right ventricular dilation after im-
plantation of first lung and crossclamping of sec-
ond pulmonary artery
1
Facilitate dissection (re-do) 1
Elective 1
Total 37
*In total, 27 patients with pulmonary hypertension underwent transplan-
tation on bypass; 4 are included in the en-bloc group.
Table IV. Graft ischemic times
Graft CPB* No-CPB p Value
First lung 307 6 67 252 6 67 0.002
Second lung 369 6 60 378 6 80 0.58
Mean 346 6 59 315 6 72 0.04
*Mean ischemic time in minutes, 6 standard deviation.
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Postoperative allograft function. Mean chest x-
ray scores for both groups were compared 0 and 24
hours after transplantation. Immediately after the
operation, the CPB group had a mean chest x-ray
score of 2.4 6 0.17 (standard error of the mean), in
comparison to 1.3 6 0.18 for the group done without
bypass (Fig. 2). At 24 hours, scores had improved to
1.8 6 0.17 in the CPB group and 1.0 6 0.16 in the
no-CPB group. At both time periods, the CPB group
had significantly more pronounced infiltrates than
did the no-CPB group (p 5 0.005). Fig. 3 details the
PO2/FiO2 ratio at various intervals after operation.
The arterial/alveolar oxygen tension ratio was better
in the no-CPB group at 12 and 24 hours after
operation (0.54 vs 0.39 at 12 hours, p 5 0.002; and
0.63 vs 0.38 at 24 hours, p 5 0.001). Both indices of
oxygenation were significantly lower in the CPB
group at 12 and 24 hours. Postoperative ECLS was
needed in 6 of 37 (16.2%) in the CPB group and in
3 of 57 (5.3%) in the no-CPB group (p 5 0.08).
Histologically proven DAD was more common in
the CPB group (69% vs 35%, p 5 0.002).
Median duration of intubation was markedly
longer in the CPB group (10 days) than in the
no-CPB group (2 days, p 5 0.002, Fig. 4). Similarly,
median length of stay in the intensive care unit was
almost twice as long in the CPB group as in the
no-CPB group (16 and 8.5 days, respectively; p 5
0.05).
Analysis of risk factors by multiple logistic regres-
sion identified several factors associated with pro-
longed postoperative intubation (defined as . 7
days, Table V). The strongest risk factor for pro-
longed intubation was use of CPB (odds ratio 5
6.2), followed by a recipient diagnosis of bronchiec-
tasis (odds ratio 5 5.9). Importantly, pulmonary
hypertension did not appear as an independent risk
factor for prolonged ventilatory support. Increasing
recipient age and earlier year of operation were also
associated with a mild increased risk of prolonged
intubation.
Death. The 30-day mortality rate was 5 of 37
(13.5%) patients in the CPB group and 4 of 57
(7.0%) patients in the no-CPB group. This differ-
ence did not reach statistical significance (p 5 0.30).
Survival at 1 year was nearly identical in the two
groups: 68% in the CPB group and 67% in the
no-CPB group.
Multiple regression analysis was applied to iden-
tify risk factors associated with early (1-month)
death. Of all possible risk factors analyzed (Table I),
none were predictive of 30-day death.
Discussion
Since the introduction of sequential single-lung
transplantation, CPB is no longer mandatory for
double-lung transplantation. Although it seems in-
tuitive that CPB, which is known to produce a
“whole-body” inflammatory response12-14 and re-
quires full systemic anticoagulation, would have a
negative impact on the function of a newly im-
planted pulmonary allograft, there remains contro-
versy over the extent to which CPB contributes to
morbidity and death. An earlier report from our
institution evaluated the effect of CPB on single-
lung, double-lung, and heart-lung recipients. This
study included 38 sequential double-lung transplan-
tations, of which 18 required CPB. Analysis of this
group showed an adverse effect of CPB on early
allograft function and significantly lower patient
survival at 1 month.6 Similar findings were reported
by Egan and associates15 in 44 patients who under-
Fig. 2. Chest x-ray (CXR) scores at 0 and 24 hours after
transplantation. Values are expressed as means 6 stan-
dard error of the mean. *p 5 0.005
Fig. 3. Posttransplantation PO2/FiO2 ratios.
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went double-lung transplantation for cystic fibrosis.
In contrast, Triantafillou and associates16 reported
no adverse effects of CPB on length of intubation,
duration of stay in the intensive care unit, and
postoperative oxygenation among sequential dou-
ble-lung recipients. Others have stated that only
prolonged duration of CPB, and not the use of CPB
per se, is detrimental to patient outcome.17
Excluding recipients with pulmonary hyperten-
sion, where we continue to believe that CPB is
mandatory to prevent acute right ventricular failure,
bypass was avoided in most patients who underwent
double-lung transplantation. In fact, excluding en-
bloc transplantations (n 5 6) and pulmonary hyper-
tensives (n 5 23) (Table III), of 65 patients “at risk”
in this series for CPB, only 8 (12.3%) required CPB.
This compares favorably with previous reports: the
Washington University group used bypass in 18 of
68 (26%) double-lung transplantations performed
with the sequential single-lung technique,16 and the
Toronto group used CPB in 10 of 31 (32%) patients
who underwent double-lung transplantations.18
In most of the recipients in this series, the need
for CPB was obvious early in the case. By far the
most common scenario (5 of 8 patients) was hypo-
tension and hypoxemia during one-lung ventilation
instituted to facilitate contralateral hilar dissection.
In only one case did hemodynamic instability appear
after implantation of the first graft and crossclamp-
ing of the second main pulmonary artery; diversion
of the entire blood flow through the newly im-
planted allograft produced acute right heart failure.
This is also somewhat different from previously
reported experiences. In one series,16 very few pa-
tients were supported by CPB during implantation
of the first allograft; the most common situation
requiring support was among those 11 of 18 (61%)
patients who became unstable when complete pul-
monary perfusion was routed to the newly im-
planted lung. The Toronto group reported equal
need for CPB both before and after implantation of
the first graft.18
With so few double-lung transplant recipients
(excluding those with pulmonary hypertension) in
our series requiring CPB, it was difficult to identify
factors that could predict in advance the need for
extracorporeal support. Among the patients in this
series, none with emphysema needed bypass (0 of
11), and only 3 of 41 (7%) recipients with cystic
fibrosis needed support. Although few in number,
bronchiectasis made up a significant proportion of
the group requiring CPB and may be a risk factor for
its use; three of nine (33%) patients with this
diagnosis were in the CPB group.
We continue to believe that, when possible, CPB
should be avoided; analysis of perioperative events
and assessment of early postoperative allograft func-
tion in this large series of patients supports this
contention. Use of CPB prolonged mean allograft
ischemic time for the CPB group by over 30 minutes
and increased the mean requirement for periopera-
tive blood transfusions by 5.4 units. By multiple
measurements, CPB had a strong negative impact
on early allograft function. Chest x-ray scores at 0
and 24 hours after the operation were significantly
worse in the CPB group. Indices of oxygenation at
12 and 24 hours after operation in the CPB group
were also well below those in the no-CPB group, and
there was a markedly greater incidence of histolog-
ically proven DAD among those in the CPB group.
Clinical indicators of impaired allograft function
also support the conclusion that CPB is deleterious.
Fig. 4. Duration of intubation. Values are expressed as
median 6 standard error of the mean.
Table V. Significant risk factors for prolonged
posttransplantation intubation (.7 days)
Risk factor p Value Odds ratio
Use of CPB 0.0004 6.2
Recipient diagnosis:
Pulmonary hypertension NS
Chronic obstructive pulmonary
disease
NS
Cystic fibrosis NS
Pulmonary fibrosis NS
Bronchiectasis 0.02 5.9
Allograft ischemic time NS
Year of operation 0.03 —
Recipient age 0.06 2.0 (age .35)
Recipient sex NS
Donor age NS
NS, Not significant.
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Median length of intubation was a brief 2 days in the
no-CPB group, in sharp contrast to a median 10 days
in the CPB group. Length of stay in the intensive
care unit was 8.5 and 16 days, respectively. The CPB
group had a threefold increased requirement for
immediate postoperative ECLS.
It is clear that the compositions of the CPB and
no-CPB groups were markedly different with regard
to diagnosis. Mandatory use of CPB in all patients
with pulmonary hypertension heavily weighted the
CPB group with these patients. To assure ourselves
that the observed negative effects of CPB were not
simply due to CPB acting as a surrogate variable, we
performed multivariate logistic regression analysis
and examined the roles of multiple variables (in-
cluding the use of CPB) on both the need for
prolonged (.7 days) ventilation and 1-month mor-
tality. The results of this analysis demonstrated that
CPB was the strongest independent predictor of the
need for prolonged intubation (odds ratio 6.2). A
diagnosis of pulmonary hypertension alone did not
emerge as an independent predictor of early allo-
graft dysfunction. Other predictors that were found
to be significant included a diagnosis of bronchiec-
tasis (odds ratio 5.9), increased recipient age, and
earlier year of operation (Table V). Similar analysis
confirmed our observation that CPB was not asso-
ciated with increased 1-month mortality. This sug-
gests that use of CPB is associated with a profound
but largely reversible negative effect on the pulmo-
nary graft after transplantation. As a final analysis,
we examined the subset of eight patients that re-
quired CPB but who did not have pulmonary hyper-
tension. All measures of graft function in this group
were remarkably similar to the remainder of the
CPB group and substantially poorer than the no-
CPB group.
In summary, in the absence of pulmonary hyper-
tension, CPB is only occasionally necessary in dou-
ble-lung transplantation. In our hands, bypass is
associated with substantial early allograft dysfunc-
tion after transplantation.
We thank Mr. Wayne Grgurich for his expert work with
the University of Pittsburgh Lung Transplant Database.
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Discussion
Dr. Frederick L. Grover (Denver, Colo.). The problems
associated with having to use CPB during lung transplan-
tation are generally accepted but not very frequently
quantified as the authors have so nicely done. Dr. Dave
Fullerton and our group demonstrated that using bypass
during experimental lung transplantation significantly im-
pairs both the endothelium-dependent and endothelium-
independent relaxation of pulmonary vasculature and thus
contributes to a significantly higher pulmonary vascular
resistance in the transplanted lung. Other investigators
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have shown increased pulmonary endothelial permeability
associated with CPB and activation of complement, leu-
kocytes, and cytokines, all of which can increase the
likelihood of damage in the newly transplanted lung
during this period of vulnerable reperfusion.
In the Pittsburgh series, CPB was used in only 8 of the
65 (12.3%) nonpulmonary hypertensive or double-lung
en-bloc patients. I believe this is one of the most impor-
tant points of this paper, that is, with the exception of the
pulmonary hypertension group, CPB is usually not re-
quired in bilateral sequential lung transplantation, partic-
ularly in the hands of an experienced group of surgeons
and anesthesiologists.
Dr. Gammie and his associates found several indicators
of decreased graft function in the CPB group, and they
also found that when possible factors leading to prolonged
intubation were analyzed using a multiple logistic regres-
sion model, the strongest risk factor was the use of CPB
followed by a diagnosis of bronchiectasis.
I reviewed in brief our experience at the University of
Colorado to see whether we had a similar experience in
over 70 lung transplantations, 22 of which have been
double sequential without pulmonary hypertension. In our
experience only four have been supported with CPB, a
rate of 18%, which is very similar to the authors’. Our
Pao2/Fio2 ratios also were decreased in the CPB group,
very similar to yours, in the early period. However, in
variation with your experience, we experienced no major
differences in early and late outcome, with our very small
group of CPB patients being extubated in 24 to 48 hours.
I have two questions. First, could there be other patient
characteristics that were not entered into your logistic
regression model that could also have a significant impact
on prolonged intubation and outcome, such as serum
albumin, weight loss, cachexia, preoperative debilitation,
that may have contributed to having to use CPB? In other
words, were the patients who had CPB sicker and there-
fore less likely to do well independent of whether they
were supported by bypass?
Dr. Gammie. Dr. Grover, we did not look at indicators
of preoperative nutritional status. Our model did include
diagnosis, donor and recipient characteristics, and opera-
tive factors that have previously been shown to be impor-
tant in outcome in this group of patients.
We have benefited from a strong institutional experi-
ence with lung transplantation and are fortunate to have
expert anesthesia colleagues. They are often able to avoid
using bypass for these patients by accepting rather severe
degrees of hypercarbia with a Pco2 of nearly 100 mm Hg,
provided that there is no ongoing hypoxemia, and they
also are fairly aggressive in their use of vasoconstrictors
and inotropic agents.
Dr. Grover. My last question relates to your average
bypass time of approximately 4 hours, which seems long.
Could it be that the variation in your results and ours is
perhaps related to the length of bypass as much as to
bypass itself?
Dr. Gammie. That could be.
Dr. Joseph Bavaria (Philadelphia, Pa.). Correct me if
I’m wrong. Was it one patient that you had who needed to
be converted to bypass after the first lung was placed?
Dr. Gammie. That’s correct.
Dr. Bavaria. In my experience that’s an absolute disas-
ter; we have never had a single patient survive. I just
wonder, did that patient survive or not? Do you remem-
ber?
Dr. Gammie. That patient did indeed experience a
rocky postoperative course, requiring ECMO for 13 days
and over a month of ventilatory support. She ultimately
survived and is doing well today.
Dr. Bavaria. That is usually a significant primary graft
dysfunction problem, and the outcome of that patient
probably has nothing to do with CPB or no CPB.
Dr. Douglas Wood (Seattle, Wash.). One question for
you. It is clear in all of our minds that CPB may negatively
affect the graft as it is going in. Though I am not sure that
your results support that conclusion, I think we certainly
may agree that is the result. Unfortunately, you have a
select group of patients, a sicker group of patients, who
are undergoing and requiring CPB than those who are
not; it would be nice to have a prospective study in which
this is randomized because there are potential advantages
to using CPB as well. One of these, in contrast to your
experience, is that our graft ischemia time is less when we
are using CPB. We will often have both lungs out before
the donor lungs arrive, so we shorten the time of recipient
pneumonectomies. There may be an advantage in de-
creasing the cross-contamination, particularly in the pa-
tient with cystic fibrosis or bronchiectasis, in having both
lungs out and the field clean before starting implantation.
Have you considered any of these effects or the negative
impact on the first transplanted lung of reperfusion with
the total cardiac output in cases without CPB?
Dr. Gammie. In answer to the last segment of your
question first, we did look at the differential radiographic
appearances of the first and second implanted lungs and
did not find a significant difference in either the CPB or
no-CPB groups. Allograft ischemic time did not fall out as
a predictor of allograft dysfunction in our multiple regres-
sion analysis. The use of CPB was identified as having the
single strongest independent effect on early graft dysfunc-
tion. These data would not support a randomized study of
CPB but rather suggest that CPB should be avoided in the
routine situation.
Dr. Robert C. Robbins (Stanford, Calif.). I agree with
Dr. Bavaria’s comment, and you have answered a couple
of questions concerning the reperfusion injury to the one
lung that has the shorter ischemic time while you are
doing the second lung. I think that Dr. Grover’s point that
your bypass times were quite long does have something to
do with your results.
Something that I have started doing is putting the first
lung in, then putting the patient on bypass to remove the
second lung and implant the second allograft. With this
approach the bypass times are certainly shorter. The right
lung is protected from high-pressure reperfusion injury
during the time the left lung is being implanted. I also
think it provides better exposure.
My question is, what about airway complications? Were
there any differences in airway complication, such as
stenoses in either of these groups?
Dr. Gammie. We did not examine that.
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Dr. Robbins. What about in practice? Do you recall
using stents in any patients? I know you might not have
looked at it specifically, but my impression is that, if you
do not use bypass, the left lung tends to be a little bit
tougher to expose, especially in the patients with cystic
fibrosis. My point is that if you put the right lung in then
you can use a short period of bypass to facilitate your
exposure for left lung implantation. This may also lessen
the injury to the right lung.
Dr. Gammie. My impression is that the airway anasto-
motic complications have been fairly evenly distributed
between the CPB and no-CPB groups.
Dr. Paul Waters (Los Angeles, Calif.). I agree with your
conclusions. I think putting the patient on bypass adds
to their possible morbidity, but I wonder if grouping the
primary pulmonary hypertension patients and the few
patients you had who had emphysema and the larger
number of patients with bronchiectasis and cystic fibro-
sis are basically the same thing when you are perform-
ing a transplantation; the cause is different. I wonder
whether it is appropriate to bunch those two groups
together. Patients with pulmonary hypertension are
completely different in the postoperative phase. The
condition tends to be very difficult to manage. These
patients tend to have more allograft dysfunction; I
wonder if you look at those groups separately what your
conclusions might be.
Dr. Gammie. That is a good question; actually we did
look at those eight patients who were nonpulmonary
hypertensive and who were on bypass, and it was really
remarkable. All measures of outcome in that group were
virtually identical to the rest of the pulmonary hyperten-
sion group. They required 18 units of blood. They were
intubated for a median 18 days, so I think that lends some
support to our hypothesis.
Dr. Waters. But you also had 38 or 28 patients with
cystic fibrosis?
Dr. Gammie. Thirty-eight of 41 recipients with cystic
fibrosis were operated on without CPB.
Dr. Waters. That is a lot of patients, and I am sure the
blood loss, just as an example, would be quite a bit more
in those patients while on bypass than the pulmonary
hypertensive patients who usually do not have a fused
pleural cavity.
Dr. Gammie. Our multiple regression analysis demon-
strates that the diagnosis of cystic fibrosis did not have an
independent negative impact on early graft function,
whereas CPB clearly did.
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